ArticleBMC psychiatry2026
Serum IL-17A and CCL20 levels and their correlation with obsessive-compulsive disorder and suicidality in schizophrenia and bipolar mood disorder.
Article in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIL-17A and CCL20 are key inflammatory mediators involved in neuroinflammation linked to schizophrenia (SCZ) and bipolar mood disorder (BMD), influencing disease severity and representing potential biomarkers and therapeutic targets. This study aimed to assess serum IL-17A and CCL20 levels in SCZ and BMD patients and explore their associations with obsessive-compulsive disorder (OCD) symptoms and suicidality.
methodsA cross-sectional study was conducted in 2024 at Ibn Sina Psychiatric Hospital, Mashhad, Iran, involving inpatients diagnosed with SCZ or BMD during acute episodes. Consecutive sampling was used to enroll eligible patients aged 18 to 65 who met the inclusion criteria, excluding those with substance use disorders, autoimmune diseases, recent infections, or on immunosuppressive therapy. Demographic and clinical data, including OCD and suicidality status, were collected via interviews and medical records. Serum IL-17A and CCL20 levels were measured using ELISA kits after overnight fasting. Statistical analyses included t-tests, Mann-Whitney U, chi-square, logistic regression, and generalized linear model tree (GLMtree) models, considering a p-value of less than 0.05 as statistically significant.
resultsThe study included patients with a mean age of 39.81 ± 10.36 years. BMD patients showed greater employment rates and more suicidal thoughts (p < 0.001). Serum IL-17A and CCL20 levels did not differ significantly between SCZ and BMD groups. Logistic regression revealed a probability inverse association between IL-17A and suicidal thoughts in BMD patients (β = -0.406). GLMtree analysis demonstrated that increased IL-17A was probably associate with greater OCD severity in females and a complex interaction with electroconvulsive therapy (ECT) history, while seemingly IL-17A's association with suicidal thoughts differed by diagnosis, ethnicity, and medication use (p < 0.05).
conclusionThe study found that suicidal thoughts and suicide cases were more common in BMD patients. Although serum IL-17A and CCL20 levels did not differ between SCZ and BMD groups, lower IL-17A were associated with greater suicidality in BMD. The relationship between IL-17A, OCD, and suicidal ideation was maybe influenced by gender, ethnicity, treatment, and diagnosis, underscoring the complex immune-psychiatric interactions in these disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.